704 related articles for article (PubMed ID: 25380901)
21. Outcomes in African American kidney transplant patients receiving tacrolimus and mycophenolic acid immunosuppression.
Narayanan M; Pankewycz O; El-Ghoroury M; Shihab F; Wiland A; McCague K; Chan L
Transplantation; 2013 Feb; 95(4):566-72. PubMed ID: 23423268
[TBL] [Abstract][Full Text] [Related]
22. Freedom from rejection and stable kidney function are excellent criteria for steroid withdrawal in tacrolimus-treated kidney transplant recipients.
Włodarczyk Z; Wałaszewski J; Perner F; Vitko S; Ostrowski M; Bachleda P; Kokot F; Klinger M; Szenohradsky P; Studenik P; Navratil P; Asztalos L; Rutkowski B; Nagy KK; Hickey D
Ann Transplant; 2002; 7(3):28-31. PubMed ID: 12465429
[TBL] [Abstract][Full Text] [Related]
23. Randomized trial of cyclosporine and tacrolimus therapy with steroid withdrawal in living-donor renal transplantation: 5-year follow-up.
Lee YJ; Kim B; Lee JE; Kim YG; Kim DJ; Kim SJ; Joh JW; Oh HY; Huh W
Transpl Int; 2010 Feb; 23(2):147-54. PubMed ID: 19744223
[TBL] [Abstract][Full Text] [Related]
24. Three-year observational follow-up of a multicenter, randomized trial on tacrolimus-based therapy with withdrawal of steroids or mycophenolate mofetil after renal transplant.
Pascual J; van Hooff JP; Salmela K; Lang P; Rigotti P; Budde K
Transplantation; 2006 Jul; 82(1):55-61. PubMed ID: 16861942
[TBL] [Abstract][Full Text] [Related]
25. Randomized trial of tacrolimus in combination with sirolimus or mycophenolate mofetil in kidney transplantation: results at 6 months.
Gonwa T; Mendez R; Yang HC; Weinstein S; Jensik S; Steinberg S;
Transplantation; 2003 Apr; 75(8):1213-20. PubMed ID: 12717205
[TBL] [Abstract][Full Text] [Related]
26. [Effectiveness and safety of conversion therapy with the combination of sirolimus with low dose cyclosporine in renal transplantation recipients: a five-year clinical observation].
Zhu L; Ding T; Wang XX; Lin ZB; Chen G
Zhonghua Yi Xue Za Zhi; 2016 May; 96(20):1556-61. PubMed ID: 27266681
[TBL] [Abstract][Full Text] [Related]
27. Donor-Specific Anti-Human Leukocyte Antigens Antibodies, Acute Rejection, Renal Function, and Histology in Kidney Transplant Recipients Receiving Tacrolimus and Everolimus.
Ferreira A; Felipe C; Cristelli M; Viana L; Basso G; Stopa S; Mansur J; Ivani M; Bessa A; Ruppel P; Aguiar W; Campos E; Gerbase-DeLima M; Proença H; Tedesco-Silva H; Medina-Pestana J
Am J Nephrol; 2017; 45(6):497-508. PubMed ID: 28511172
[TBL] [Abstract][Full Text] [Related]
28. A randomized trial of three renal transplant induction antibodies: early comparison of tacrolimus, mycophenolate mofetil, and steroid dosing, and newer immune-monitoring.
Ciancio G; Burke GW; Gaynor JJ; Carreno MR; Cirocco RE; Mathew JM; Mattiazzi A; Cordovilla T; Roth D; Kupin W; Rosen A; Esquenazi V; Tzakis AG; Miller J
Transplantation; 2005 Aug; 80(4):457-65. PubMed ID: 16123718
[TBL] [Abstract][Full Text] [Related]
29. De novo sirolimus with low-dose tacrolimus versus full-dose tacrolimus with mycophenolate mofetil after heart transplantation--8-year results.
Guethoff S; Stroeh K; Grinninger C; Koenig MA; Kleinert EC; Rieger A; Mayr T; von Ziegler F; Reichart B; Hagl C; Schramm R; Kaczmarek I; Meiser BM
J Heart Lung Transplant; 2015 May; 34(5):634-42. PubMed ID: 25701373
[TBL] [Abstract][Full Text] [Related]
30. Albuminuria after renal transplantation: maintenance with sirolimus/low-dose tacrolimus vs. mycophenolate mofetil/high-dose tacrolimus.
Miles CD; Skorupa JY; Sandoz JP; Rigley TH; Nielsen KJ; Stevens RB
Clin Transplant; 2011; 25(6):898-904. PubMed ID: 21077952
[TBL] [Abstract][Full Text] [Related]
31. Mechanistic analyses in kidney transplant recipients prospectively randomized to two steroid free regimen-Low dose Tacrolimus with Everolimus versus standard dose Tacrolimus with Mycophenolate Mofetil.
Traitanon O; Mathew JM; Shetty A; Bontha SV; Maluf DG; El Kassis Y; Park SH; Han J; Ansari MJ; Leventhal JR; Mas V; Gallon L
PLoS One; 2019; 14(5):e0216300. PubMed ID: 31136582
[TBL] [Abstract][Full Text] [Related]
32. Optimizing tacrolimus therapy in the maintenance of renal allografts: 12-month results.
Bolin P; Shihab FS; Mulloy L; Henning AK; Gao J; Bartucci M; Holman J; First MR;
Transplantation; 2008 Jul; 86(1):88-95. PubMed ID: 18622283
[TBL] [Abstract][Full Text] [Related]
33. Tacrolimus monotherapy following alemtuzumab induction in combined kidney-pancreas transplantation: results of a prospective randomized trial.
Bösmüller C; Ollinger R; Sieb M; Weissenbacher A; Schneeberger S; Pratschke J; Margreiter R
Ann Transplant; 2012 Dec; 17(4):45-51. PubMed ID: 23274323
[TBL] [Abstract][Full Text] [Related]
34. Tacrolimus or cyclosporine: which is the better partner for mycophenolate mofetil in heart transplant recipients?
Meiser BM; Groetzner J; Kaczmarek I; Landwehr P; Müller M; Jung S; Uberfuhr P; Fraunberger P; Stempfle HU; Weis M; Reichart B
Transplantation; 2004 Aug; 78(4):591-8. PubMed ID: 15446320
[TBL] [Abstract][Full Text] [Related]
35. Impact of Mycophenolate Mofetil Dose Reduction on Allograft Outcomes in Kidney Transplant Recipients on Tacrolimus-Based Regimens: A Systematic Review.
Su VCh; Greanya ED; Ensom MH
Ann Pharmacother; 2011 Feb; 45(2):248-57. PubMed ID: 21304036
[TBL] [Abstract][Full Text] [Related]
36. Effective and Safe Reduction of Conventional Immunosuppressants Using Everolimus in Maintenance Kidney Transplant Recipients.
Nanmoku K; Kurosawa A; Kubo T; Shinzato T; Shimizu T; Kimura T; Yagisawa T
Transplant Proc; 2017 Oct; 49(8):1724-1728. PubMed ID: 28923615
[TBL] [Abstract][Full Text] [Related]
37. Quadruple immunosuppression with basiliximab, tacrolimus, mycophenolate mofetil and prednisone is safe and effective for renal transplantation.
Miura M; Harada H; Fukuzawa N; Iwami D; Taniguchi A; Seki T; Togashi M; Ogawa Y; Satoh H; Hirano T
Clin Transplant; 2005; 19 Suppl 14():54-8. PubMed ID: 15955170
[TBL] [Abstract][Full Text] [Related]
38. A prospective, randomized trial to compare tacrolimus and prednisone with and without mycophenolate mofetil in patients undergoing renal transplantation: first report.
Shapiro R; Jordan ML; Scantlebury VP; Vivas C; Gritsch HA; Casavilla FA; McCauley J; Johnston JR; Randhawa P; Irish W; Hakala TR; Fung JJ; Starzl TE
J Urol; 1998 Dec; 160(6 Pt 1):1982-5; discussion 1985-6. PubMed ID: 9817305
[TBL] [Abstract][Full Text] [Related]
39. Influence of tacrolimus plus mycophenolate mofetil regimens on acute rejection rate and diabetes mellitus development in renal transplant recipients.
Demirbaş A; Tuncer M; Yavuz A; Gürkan A; Kaçar S; Cetinkaya R; Tekin S; Akbaş SH; Akaydin M; Ersoy F; Yakupoğlu G
Transplant Proc; 2004; 36(1):175-7. PubMed ID: 15013338
[TBL] [Abstract][Full Text] [Related]
40. The use of an anti-CD25 monoclonal antibody and mycophenolate mofetil enables the use of a low-dose tacrolimus and early withdrawal of steroids in renal transplant recipients.
Kuypers DR; Evenepoel P; Maes B; Coosemans W; Pirenne J; Vanrenterghem Y
Clin Transplant; 2003 Jun; 17(3):234-41. PubMed ID: 12780674
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
